GYKI 52466

Drug Profile

GYKI 52466

Latest Information Update: 25 May 2001

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator IVAX Drug Research Institute
  • Class Antiepileptic drugs; Muscle relaxants; Neuroprotectants; Small molecules
  • Mechanism of Action AMPA receptor antagonists; Glutamate receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alzheimer's disease; Epilepsy; Neurological disorders

Most Recent Events

  • 25 May 2001 Data have been added to the Neurological Disorders pharmacodynamics section
  • 08 Aug 1995 Discontinued-Preclinical for Alzheimer's disease in Hungary (Unknown route)
  • 08 Aug 1995 Discontinued-Preclinical for Alzheimer's disease in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top